Mayne Pharma Group Limited (MYX:ASX)

34.0¢

right-arrow Created with Sketch. -0.01 (-2.86%)
MCAP $617.6M
Last trade 16.10pm 19/10/2021 20mins delayed

Latest Announcements

19/10/2021MYXMayne Pharma Group Limited
19/10/2021MYXMayne Pharma Group Limited
07/10/2021MYXMayne Pharma Group Limited
05/10/2021MYXMayne Pharma Group Limited
04/10/2021MYXMayne Pharma Group Limited
04/10/2021MYXMayne Pharma Group Limited
29/09/2021MYXMayne Pharma Group Limited
27/09/2021MYXMayne Pharma Group Limited

Company Overview

Mayne Pharma Group Ltd is an Australia-based specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals. The Company’s segments include Generic Products (GPD), Specialty Products (SPD), Metrics Contract Services (MCS), and Mayne Pharma International (MPI). The GPD segment is engaged in the distribution of generic pharmaceutical products in the United States. GPD segment engaged in the distribution of generic pharmaceutical products in the United States. MCS segment is providing contract pharmaceutical development and manufacturing services to third party customers principally in the United States. SPD segment is distributing specialty pharmaceutical products in the United States. MPI segment manufactures and sells branded and generic pharmaceutical products globally and provisions of contract manufacturing services to third party customers within Australia.

MYX in the news

Mayne Pharma (MYX) faces a class action over alleged failures to inform…
Mayne Pharma (MYX) and Mithra Pharmaceuticals have received approval for its combined…
H1 FY21 proved to be a challenging period for Mayne Pharma Group…
Mayne Pharma (MYX) has received feedback from the U.S. Food and Drug…

Search Previous Announcements